![Shunichi Morimoto](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Shunichi Morimoto
No más puestos en curso
Fortuna: 2 M $ al 31/05/2024
Perfil
Shunichi Morimoto was the Chairman of Institute of Immunology Co., Ltd.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
PHOENIXBIO CO., LTD.
12.56% | 31/03/2023 | 506 000 ( 12.56% ) | 2 M $ | 31/05/2024 |
Antiguos cargos conocidos de Shunichi Morimoto.
Empresas | Cargo | Fin |
---|---|---|
Institute of Immunology Co., Ltd.
![]() Institute of Immunology Co., Ltd. Medical SpecialtiesHealth Technology Institute of Immunology Co., Ltd. engages in the manufacture and sale of diagnostic reagents and monoclonal antibodies for research purpose. It develops and produces Enzyme Immunoassay (EIA) kits related to infectious diseases such as hepatitis B as well as those for human hepatocellular growth factor determination. The firm also offers EIA kits for detecting hepatitis E virus antibody and for determining the genotypes of hepatitis B virus and offers immunization of 3 mice, evaluation, fusion, screening, cloning, ascites production and purification services to the research, clinical and medical industries. The company was founded by Tetsuo Nakamura on August 18, 1979 and is headquartered in Tokyo, Japan. | Presidente | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Institute of Immunology Co., Ltd.
![]() Institute of Immunology Co., Ltd. Medical SpecialtiesHealth Technology Institute of Immunology Co., Ltd. engages in the manufacture and sale of diagnostic reagents and monoclonal antibodies for research purpose. It develops and produces Enzyme Immunoassay (EIA) kits related to infectious diseases such as hepatitis B as well as those for human hepatocellular growth factor determination. The firm also offers EIA kits for detecting hepatitis E virus antibody and for determining the genotypes of hepatitis B virus and offers immunization of 3 mice, evaluation, fusion, screening, cloning, ascites production and purification services to the research, clinical and medical industries. The company was founded by Tetsuo Nakamura on August 18, 1979 and is headquartered in Tokyo, Japan. | Health Technology |
- Bolsa de valores
- Insiders
- Shunichi Morimoto